FDA will hold a two-day public meeting on July 2324, 2026 to discuss seven peptide bulk drug substances nominated for possible inclusion on the 503A Bulks List a wonky-sounding list that, in practice, helps determine what traditional compounding pharmacies can legally make when a patient needs something that isnt available as an FDA-approved drug
Sometimes called the wolverine peptide, BPC-157 is marketed as an injury recovery aid and animal studies have been positive
BPC-157 and TB-500 may work better in tandem for certain studies
BPC-157 is not approved by Health Canada for human use
In rodent models, BPC-157 demonstrated a wide therapeutic index with no observed hepatotoxicity, nephrotoxicity, or neurotoxicity across multiple dosing regimens. Sikiric et al., Regenerative Pharmacology Reported Side Effects (Rare) While side effects are rare, some users report: Peptides like BPC-157 generally exhibit low immunogenicity and low systemic toxicity, though user-specific variables such as injection technique or gut sensitivity may influence short-term side effects. [Clinical Peptide Society Review, 2021] Is BPC-157 Safe for Long-Term Use
Regulatory Simplicity: As a dietary supplement, oral BPC-157 does not require prescriptions, medical consultations, or relationships with compounding pharmacies that characterize many injectable peptide protocols